Quick Answer
Greenwich LifeSciences, Inc. reported Operating Income Loss of -$16.01 million for the year ending 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -71.7% in Operating Income Loss from 2023 to 2024.
- This data is from Greenwich LifeSciences, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$336.0 thousand | Q1 2020: -$244.6 thousand | Q2 2020: -$210.4 thousand | Q3 2020: -$256.9 thousand | Q1 2021: -$600.6 thousand | Q2 2021: -$753.4 thousand | Q3 2021: -$866.7 thousand | Q1 2022: -$1.99 million | Q2 2022: -$773.3 thousand | Q3 2022: -$2.38 million | Q1 2023: -$2.24 million | Q2 2023: -$1.75 million | Q3 2023: -$2.50 million | Q1 2024: -$2.54 million | Q2 2024: -$2.66 million | Q3 2024: -$2.73 million | Q1 2025: -$3.28 million | Q2 2025: -$4.05 million | Q3 2025: -$4.17 million.
- Over the full 6 years of available data (2019 to 2024), Greenwich LifeSciences, Inc.'s Operating Income Loss has declined by 367.5%.
- Historical annual values: Fiscal year 2024: -$16.01 million | Fiscal year 2023: -$9.33 million | Fiscal year 2022: -$8.04 million | Fiscal year 2021: -$4.60 million | Fiscal year 2020: -$1.86 million | Fiscal year 2019: -$3.43 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: